Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Exelixis, Inc. (NASDAQ: EXEL).

Full DD Report for EXEL

You must become a subscriber to view this report.


Recent News from (NASDAQ: EXEL)

Exelixis' Cabometyx expands presence in cancer care guidelines
The National Comprehensive Cancer Network has updated its Clinical Practice Guidelines to include new recommendations for Exelixis' (NASDAQ: EXEL ) CABOMETYX (cabozantinib), including the treatment of advanced renal cell carcinoma regardless of risk status of the patient. More news on: E...
Source: SeekingAlpha
Date: September, 07 2018 08:30
Exelixis Announces New Recommendations for CABOMETYX® (Cabozantinib) Tablets in Updated National Comprehensive Cancer Network Clinical Practice Guidelines
– CABOMETYX recommended for the treatment of previously untreated advanced renal cell carcinoma across all patient risk groups – Exelixis, Inc. (NASDAQ:EXEL) today announced that the National Comprehensive Cancer Network (NCCN) updated its Clinical Practice Guideline...
Source: Business Wire
Date: September, 07 2018 08:00
Buy United Parcel Service - Cramer's Lightning Round (9/6/18)
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday, September 6 . Bullish Calls Exelon (EXC): Cramer likes the stock, as interest rates are going up. AbbVie (ABBV): Cramer likes this stock at $92. However, he thinks Abbott Labs (ABT) is a better ...
Source: SeekingAlpha
Date: September, 07 2018 07:17
Exelixis: Elucidating The Upcoming Clinical Binary For Cabozantinib
Such a study indicates that the greatest investment reward comes to those who by good luck or good sense find the occasional company that over the years can grow in sales and profits far more than the industry as a whole. It further shows that when we believe we have found such a company we h...
Source: SeekingAlpha
Date: September, 06 2018 18:34
Exelixis to Present at the Morgan Stanley Global Health Care Conference on September 12, 2018
— Presentation to be webcast on www.exelixis.com — Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will provide an overview of the company at the Morgan Stanley Global He...
Source: Business Wire
Date: September, 05 2018 16:05
Today's Research Reports on Trending Tickers: Exelixis and bluebird bio
NEW YORK, NY / ACCESSWIRE / August 28, 2018 / U.S. markets rose Monday, with the S&P 500 and Nasdaq finishing at new records for the second consecutive session, on news of the new trade agreement with the U.S. and Mexico. The Dow Jones Industrial Average jumped 1.01 percent to close at 2...
Source: ACCESSWIRE IA
Date: August, 28 2018 08:00
Exelixis: Buy Or Sell On The Dip, Subscriber Query
The meteoric rise in Exelixis stock ( EXEL ) from around $1ish to beyond $25 was due to the excellent data showed by cabozantinib, cabo in advanced renal cell cancer, RCC which led to its use as the first line in intermediate to poor risk RCC. Considering the target market of approx. 60,00...
Source: SeekingAlpha
Date: August, 27 2018 15:04
Recent Analysis Shows KB Home, Sleep Number, Exelixis, Sprint, PayPal, and Halozyme Therapeutics Market Influences - Renewed Outlook, Key Drivers of Growth
NEW YORK, Aug. 23, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of KB Home (NYSE:KBH), Sleep Number Corporation  (NASDAQ:SNBR), Exelixi...
Source: GlobeNewswire
Date: August, 23 2018 10:30
Your Cancer Highlight: The Study That Could Bridge The New Key Competitors In Kidney Cancer
Of all the forms of cancer that can affect the genitourinary tract, renal cell carcinoma (kidney cancer) has become one of the hotbeds for competition, largely among a boatload of tyrosine kinase inhibitor developers, including Pfizer ( PFE ), Roche ( RHHBF ), Novartis ( NVS ), and Eisai ( ESA...
Source: SeekingAlpha
Date: August, 23 2018 08:00
Exelixis: Existential Threats Linger Despite Growing Revenues
Exelixis ( EXEL ) continues to experience robust growth within their cabozantinib franchise, particularly within the renal cell carcinoma arena. However, the revenue growth may be already "baked in" to an extent and Exelixis lacks recent clinical wins. As a result, shares prices are suffering....
Source: SeekingAlpha
Date: August, 22 2018 03:53

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-0818.5618.5518.7918.232,166,911
2018-05-1720.5921.5621.634420.505,222,207
2018-02-2629.8029.5329.9429.232,673,016
2018-02-2329.1029.5129.5128.441,909,403
2018-02-2229.2329.1029.3928.9611,656,012

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-07383,076564,12867.9059Short
2018-12-06566,336992,45957.0639Short
2018-12-041,023,1991,474,54369.3909Short
2018-12-03490,2421,137,98743.0798Short
2018-11-30237,293680,78634.8557Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on EXEL.


About Exelixis, Inc. (NASDAQ: EXEL)

Logo for Exelixis, Inc. (NASDAQ: EXEL)

Not available

 

Contact Information

 

 

Current Management

  • George A. Scangos / President, CEO
  • Glen Y. Sato / CFO

Current Share Structure

  • Market Cap: $6,059,042,816 - 05/16/2018
  • Issue and Outstanding: 296,866,380 - 04/23/2018

 


Recent Filings from (NASDAQ: EXEL)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 02 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 02 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 12 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 12 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: April, 09 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: April, 09 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: April, 09 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 09 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: April, 09 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: March, 05 2018

 

 


Daily Technical Chart for (NASDAQ: EXEL)

Daily Technical Chart for (NASDAQ: EXEL)


Stay tuned for daily updates and more on (NASDAQ: EXEL)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: EXEL)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in EXEL is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of EXEL and does not buy, sell, or trade any shares of EXEL. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/